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on each treatment modality, PD was associated with a higherComparative hospitalization of hemodialysis and peritoneal
rate of hospitalization when analyzed according to the type ofdialysis patients in Canada.
dialysis in use at baseline (RR 1.10, 95% CI, 1.07 to 1.13, P ,Background. Most comparisons of hemodialysis (HD) and
0.001) and according to the type of dialysis in use three monthsperitoneal dialysis (PD) have used mortality as an outcome.
after study entry (RR 1.26, 95% CI, 1.23 to 1.30, P , 0.001).Relatively few studies have directly compared the hospitaliza-
Conclusions. Conclusions regarding comparative hospital-tion rates, an outcome of perhaps equal importance, of patients
ization rates are heavily dependent on the analytic startingusing these different dialysis modalities.
point and on whether intention-to-treat or treatment-receivedMethods. Eight hundred twenty-two consecutive patients at
analyses are used. When early treatment switches are ac-11 Canadian institutions with irreversible renal failure had an
counted for, HD is associated with a lower rate of hospitaliza-extensive assessment of comorbid illness and initial mode of
tion than PD, but the effect is modest.dialysis collected prospectively immediately prior to starting
dialysis therapy. The cohort was assembled between March
1993 and November 1994. The mean follow-up was 24 months.
Admission data were used to compare hospitalization rates in
The two major modes of dialysis used in clinical practiceHD and PD.
today, hemodialysis (HD) and peritoneal dialysis (PD),Results. Thirty-four percent of patients at baseline and 50%
are very different in terms of technique and physiology.at three months used PD. Twenty-five percent of HD and 32%
of PD patients switched dialysis modality at least once after Although one modality is frequently preferable to another
their first treatment (P 5 NS). Nine percent of HD patients because of an individual patient’s abilities, medical prob-
and 30% of PD patients switched modality after three months
lems, or geographic location, an individual’s choice of(P , 0.001). Total comorbidity was higher in HD patients at
treatment is sometimes difficult given the fact that thebaseline (P , 0.001) and at three months (P 5 0.001). The
effect of dialysis modality on patient outcome is contro-overall hospitalization rate was 40.2 days per 1000 patient days
after baseline and 38.0 days per 1000 patient days after three versial. Recent studies have shown that there is no differ-
months. When an adjustment was made for baseline comorbid ence in mortality in these two groups of patients, particu-
conditions, patients on PD had a lower rate of hospitalization larly when comorbid illness and acuity of onset of renalin intention-to-treat analysis according to the type of dialysis
failure are taken into consideration (abstract; Collins etin use at baseline (RR 0.85, 95% CI, 0.82 to 0.87, P , 0.001),
al, J Am Soc Nephrol 9:204A, 1998) [1, 2]. In additionbut a higher rate according to the type of dialysis in use three
months after study entry (RR 1.31, 95% CI, 1.27 to 1.34, P , to mortality, however, patient morbidity is an important
0.001). In analyses based on the amount of time actually spent outcome that may be influenced by the type of dialysis
received.
Although patient morbidity clearly extends beyond
Key words: dialysis modalities, hospitalization rates, patient outcome
hospitalization, hospital admission data are frequentlyand dialysis, Canadian HD mortality, morbidity analysis, end-stage
renal disease. used as an objective measure of morbidity. In addition
to the obvious economic implications, it has been shownReceived for publication September 14, 1999
that hospitalization has an important negative effect onand in revised form November 29, 1999
Accepted for publication December 27, 1999 quality of life [3, 4]. The majority of the studies compar-
ing HD and PD to date have used patient mortalityÓ 2000 by the International Society of Nephrology
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as the outcome. Relatively few studies have compared end-stage renal disease, original renal disease, pattern
hospitalization rates in the two modalities, and small of onset of renal failure (acute, acute-on-chronic, or
sample size or the fact that they are based on a single chronic), age, sex, race, presence and duration of diabe-
treatment center has limited many of these. Although tes, presence of a treated arrhythmia, presence or history
some investigators have shown no difference in hospital- of angina, presence or history of myocardial infarction,
ization rates between the two groups [5–8], other studies presence or history of congestive heart failure, presence
have shown a higher rate in those patients treated with or history of peripheral vascular disease, presence of
PD [9–15]. It is possible that differences in case mix could chronic lung disease, presence of coma or severe cerebral
account for the discordant conclusions from different disease, presence of severe liver disease, presence of
studies, as the availability and quality of comorbidity malignancy, blood dyscrasia, or myeloma, serum albu-
data have varied. Ideally, such data should be extensive min, height, weight, clinical impression of malnutrition,
and collected prospectively. The optimal study design presence of systemic sepsis, presence of shock, and need
for a comparison of hospitalization rates in different for ventilatory support. The definitions for each of these
dialysis modalities is a randomized trial. Such a study variables have been previously published in detail [17].
would be very difficult to conduct given the ethical and These comorbidity data were used to calculate a prog-
logistic problems that arise. Longitudinal observational nostic score derived from a previous study of patients
studies with comprehensive comorbidity data therefore starting maintenance dialysis therapy. This score incor-
remain the most feasible way to address this question. porated an individual patient’s age, the presence and/or
In a previous study, we developed a scoring system severity of cardiac failure, coronary artery disease, ar-
based on age and comorbidity present at the onset of rhythmia, peripheral vascular disease, malignancy, coma,
end-stage renal disease to aid in the prediction of early shock, severe liver disease, and requirement for mechani-
death of patients beginning dialysis therapy [16]. This cal ventilation. The resultant score could range from 1
scoring system was further evaluated with respect to its to 22, with higher values reflecting a higher burden of
ability to predict death within six months of starting comorbid illness.
dialysis in a separate prospective, multicenter, observa- Data regarding dialysis technique and hospitalization
tional study of 822 patients [17]. In the latter study, each were gathered retrospectively. Each patient’s chart was
patient had a detailed assessment of comorbid illness thoroughly reviewed to obtain the dates of dialysis mo-
immediately prior to his or her first dialysis treatment dality switches and for each hospitalization up to Janu-
and was followed until death. Given the extent of comor- ary 1, 1998.
bidity data available, this cohort represented an opportu-
nity to control for potential case mix imbalances when Analysis
comparing the hospitalization rates of these two groups
The major outcome studied was the total number ofof patients. We therefore extended the follow-up dura-
days of hospitalization in the study period relative to thetion and in this article report the comparative hospital-
survival of each patient. Admissions that preceded orization rates for patients treated with HD and PD, with
coincided with the date of study entry were not includedand without adjustment for comorbidity.
in the outcome variable calculation. Poisson regression
was the primary technique used to compare hospitaliza-
METHODS tion rates for HD and PD [18, 19].
Hospitalization was compared in two separate timePatients
frames: from baseline and from three months. This de-This prospective study used a cohort of patients with
sign was chosen because (1) PD patients frequently haveend-stage renal disease originally assembled for a study
a brief course of HD while waiting for catheter place-regarding the prediction of early death for patients start-
ment, training, etc., and (2) acute indications for dialysising dialysis treatment [17]. The cohort was assembled
are preferentially treated with HD. Patients were cen-between March 1993 and November 1994. Consecutive
sored at the time of renal transplantation or on reachingpatients with renal failure of any cause that was consid-
the time of final follow-up on dialysis therapy.ered irreversible and who started dialysis at any of 11
In intention-to-treat analyses, treatment groups wereparticipating Canadian centers were entered into the
determined by the initial mode of dialysis used and, instudy. These centers were all university affiliated and
separate analyses, the mode of dialysis in use threewere located in the following Canadian cities: St. John’s,
months after study entry. Patients were considered asHalifax, Saint John, Montreal, Toronto, London, Winni-
remaining on that therapy from that time point onward.peg, Calgary, Edmonton, and Vancouver.
In treatment-received analyses, the dates of modality
Data collection switches were used to calculate the amount of time indi-
vidual patients actually spent receiving each treatment.The following data were collected at study entry: initial
mode of dialysis (HD or PD), date of first dialysis for Hospitalization was attributed to the mode of dialysis in
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Table 1. Cohort characteristics at study entry according to first modality of dialysis used
Variable HD (N 5 540) PD (N 5 282) P value
% Male 58.7 59.9 NS
% Caucasian 78.9 81.4 NS
% Acute or acute-on-chronic onset 24.8 7.9 ,0.001
% Diabetes 35.9 36.9 NS
% Cardiac failure 39.3 26.5 ,0.001
% Myocardial infarction 19.6 14.0 0.05
% Peripheral vascular disease 18.0 13.3 NS
% Malignancy 4.3 2.5 NS
% Dysrrhythmia 9.3 3.2 0.003
Age 59.4 (58.1–60.7) 56.1 (54.2–58.0) 0.004
Body mass index 25.6 (25.1–26.1) 25.0 (24.4–25.6) NS
Albumin 33.6 (33.1–34.1) 35.0 (34.3–35.7) 0.004
Hemoglobin 88.7 (87.4–90.0) 92.3 (90.4–94.2) 0.003
Diastolic blood pressure 78.7 (77.4–80.0) 80.1 (78.6–81.6) NS
Systolic blood pressure 147.4 (145–150) 145.1 (142–148) NS
Total co-morbidity scorea 4.0 (3.78–4.22) 3.1 (2.87–3.33) ,0.001
Etiology of renal failure %
Glomerulonephritis 18.9 18.3 reference
Diabetes 27.8 31.5 NS
Hypertension 15.7 13.6 NS
Renovascular 6.3 4.3 NS
Interstitial disease 1.5 3.6 NS
Polycystic kidney 3.9 8.2 0.01
Other 17.0 11.1 0.02
Unknown 8.9 9.0 NS
Parentheses indicate 95% confidence intervals. Abbreviation is NS, not statistically significant.
aScore based on age, requirement for mechanical ventilation, presence and/or severity of cardiac failure, ischemic heart disease, arrhythmia, peripheral vascular
disease, malignancy, coma, severe liver disease, or shock (see text)
use at the time of each hospital admission. Separate analy- had their etiology classified as “other” (17.0 vs. 11.1%,
P 5 0.02).ses were performed using all treatment time and hospital
The total comorbidity score was significantly higheradmissions after study entry and after three months.
in HD compared with PD patients at baseline (4.0, 95%The reasons for hospitalization were studied as a sec-
CI, 3.8 to 4.2 vs. 3.1, 95% CI, 2.9 to 3.3, P , 0.001) andondary outcome. The rate of admission for each diagno-
at three months (3.7, 95% CI, 3.5 to 3.9 vs. 3.2, 95% CI,sis was compared based on the mode of dialysis in use
3.0 to 3.4, P 5 0.001).at baseline and at three months.
For PD patients at baseline, the mean volume of dial-
ysis solution used per day was 8.0 L/day (95% CI, 7.6
RESULTS to 8.4 L/day, N 5 174); for HD patients, the mean num-
ber of hours per week of treatment was 10.1 h/weekPatient and treatment characteristics
(95% CI, 9.9 to 10.3 h/week, N 5 421). At three months,Eight hundred twenty-two patients were enrolled in
the mean volume of dialysis solution used per day by PD
the study. PD was used by 34% of patients at baseline
patients was 8.3 L/day (95% CI, 8.1 to 8.5 L/day, N 5
and 50% at three months. Mean follow-up was 24.0 (95% 294), and HD patients received a mean of 10.5 h/week
CI, 22.8 to 25.2) months, with a maximum follow-up time (95% CI, 10.3 to 10.7 h/week, N 5 280) of dialysis. At
of 56.1 months. six months, patients on PD used 8.5 L/day of dialysis
Table 1 indicates the cohort characteristics at study solution (95% CI, 8.2 to 8.8 l/day, N 5 261), and HD
entry according to the initial mode of dialysis therapy. At patients received 10.5 h/week of dialysis (95% CI, 10.3
baseline, patients on HD differed from those on PD with to 10.7 h/week, N 5 221).
respect to age, initial hemoglobin, and serum albumin.
OutcomesDifferences were present in the proportion of patients
with acute or acute-on-chronic onset of renal failure, The principal study outcomes are shown in Table 2.
myocardial infarction, cardiac failure, and arrhythmia. The hospitalization rate was higher for patients using
The spectrum of original cause of renal failure was simi- HD as their initial therapy compared with those using
lar in both groups of patients at baseline, although a PD (43.68 vs. 33.23 hospitalized days/1000 patient days,
higher proportion of PD patients had polycystic kidney P , 0.001). When the mode of dialysis in use at three
months was used to define the groups, precisely the oppo-disease (8.2 vs. 3.9%, P 5 0.01) and more HD patients
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Table 2. Principal outcomes according to modality of dialysis used at baseline and three months
Baselinea Month 3b
Outcome HD (N 5 540) PD (N 5 282) HD (N 5 351) PD (N 5 354)
Hospital days/1000 patient-days 43.68 33.23 32.99 42.79
P ,0.001 ,0.001
Number of admissions/1000 patient-days 4.61 3.50 3.48 3.31
P ,0.001 NS
Renal transplant 112 (20.7%) 86 (30.8%) 77 (21.9%) 105 (29.7%)
P 50.002 50.02
Death 248 (45.9%) 93 (33.3%) 145 (41.3%) 126 (35.6%)
P 50.001 NS
Switch of therapy 137 (25.4%) 87 (31.9%) 33 (9.4%) 106 (29.9%)
P NS ,0.001
Abbreviations are: HD, hemodialysis; PD, peritoneal dialysis; NS, not statistically significant.
aAnytime after starting therapy
bExcluding events prior–three months after study entry
site was found, with patients treated with HD having into the study (PD/HD RR 1.10, 95% CI, 1.07 to 1.13,
P , 0.001) and when only admissions after 90 dayslower hospitalization rates than those on PD (32.99 vs.
42.79 hospitalized days/1000 patient days, P , 0.001). (PD/HD RR 1.26, 95% CI, 1.23 to 1.30, P , 0.001)
were considered. The effects of the covariables were veryPatients who began therapy with HD had more admis-
sions compared with patients treated with PD (4.61/1000 similar to those found in the intention-to-treat models.
Hospitalization rates associated with specific diagno-patient days vs. 3.50/1000 patient days, P , 0.001), but
a difference was not found when the mode of dialysis at ses for both groups of dialysis patients are shown in
Table 4. These data were analyzed in an intention-to-three months was used to define the groups.
The overall mortality was 41%. Twenty-four percent treat fashion (that is, patients were assigned to treatment
groups based on the mode of dialysis in use at the initia-of patients underwent renal transplantation within the
study period. A high proportion of HD and PD patients tion of dialysis treatment and at three months) and are
not adjusted. As discussed previously in this article, aunderwent at least one switch in their mode of dialysis
treatment within the study period (Table 2). In the base- high proportion of patients in both treatment groups
switched therapy at some point, explaining the occur-line groups, 25.4% of HD and 31.9% of PD patients
ultimately switched therapy (P 5 NS). Patients who were rence of treatment-specific diagnoses (for example, peri-
tonitis) in both groups. As expected, days hospitalizedon HD at three months were less likely to undergo a
switch in the future than patients on PD (9.4 vs. 29.9%, for peritonitis were higher in PD patients and days hospi-
talized for line infections were higher in HD patients atP , 0.001).
Table 3 shows the rate ratios for hospitalization using both time points. The hospitalization rate for cardiovas-
cular disease (angina, myocardial infarction, peripheralPoisson regression to adjust for age, male gender, acuity
of onset of renal failure, diabetes, cardiac failure, myo- vascular disease, stroke, and transient ischemic attacks)
was similar in both groups at baseline, as was the hospi-cardial infarction, and peripheral vascular disease, as
well as the mode of dialysis used. In the intention-to- talization rate for cardiac failure. After three months,
however, the hospitalization rate for cardiovascular dis-treat models, PD was associated with a lower hospitaliza-
tion rate relative to HD (PD/HD RR 0.85, 95% CI, 0.82 ease was substantially higher in PD patients (13.73 vs.
6.53 days/1000 patient days, P , 0.001). HD patientsto 0.87, P , 0.001) when the initial mode of dialysis
was used to define treatment groups, but again had the had more days hospitalized for infectious illness than
PD patients (6.51 vs. 1.67 days/1000 patient days, P ,opposite effect in the groups based on the mode of dial-
ysis in use at three months (PD/HD RR 1.31, 95% CI, 0.001 at baseline, 4.89 vs. 2.42 days/1000 patient days,
P , 0.001 at 3 months). When all dialysis-related reasons1.27 to 1.34, P , 0.001). All covariables were found to
be highly significant using baseline groups; in the groups for admission were considered (access creation, access
infection, peritonitis, arteriovenous access thrombosis,defined at three months, acute onset of renal failure and
the presence of peripheral vascular disease were the only dialysis inadequacy, and other dialysis related diagno-
ses), patients on PD had significantly higher hospitaliza-factors not found to be statistically significant. The pres-
ence of diabetes was the strongest predictor of increased tion rates after baseline and after three months (12.00
vs. 10.03 days/1000 patient days, P , 0.001, and 12.78hospital utilization, more than doubling the hospitaliza-
tion rate. The treatment-received models showed that vs. 7.37 days/1000 patient days, P , 0.001, respectively).
Those admission diagnoses not listed in Table 4 accountedPD was associated with higher hospitalization rates rela-
tive to HD both when all hospital admissions after entry for less than 5% of overall admissions.
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Table 3. Hospitalization rate ratios, adjusted using Poisson regression
Baseline 3 months
Factor Rate ratio P value Rate ratio P value
Intention-to-treat
Peritoneal Dialysis 0.85 (0.82–0.87) ,0.001 1.31 (1.27–1.34) ,0.001
Age . median 1.33 (1.29–1.36) ,0.001 1.25 (1.21–1.29) ,0.001
Acute or acute-on-chronic renal failure 1.06 (1.02–1.10) 50.003 1.00 (0.96–1.05) NS
Cardiac failure 1.10 (1.07–1.13) ,0.001 1.16 (1.13–1.20) ,0.001
Diabetes 2.02 (1.96–2.07) ,0.001 2.16 (2.09–2.22) ,0.001
Male 0.80 (0.78–0.83) ,0.001 0.75 (0.73–0.77) ,0.001
Myocardial infarction 1.06 (1.02–1.10) 50.001 1.11 (1.07–1.15) ,0.001
Peripheral vascular disease 1.08 (1.05–1.12) ,0.001 0.96 (0.92–1.00) NS
Treatment-received
Peritoneal Dialysis 1.10 (1.07–1.13) ,0.001 1.26 (1.23–1.30) ,0.001
Age . median 1.34 (1.30–1.38) ,0.001 1.25 (1.21–1.29) ,0.001
Acute or acute-on-chronic renal failure 1.11 (1.07–1.15) ,0.001 0.98 (0.94–1.03) NS
Cardiac failure 1.11 (1.08–1.14) ,0.001 1.14 (1.11–1.18) ,0.001
Diabetes 2.03 (1.98–2.09) ,0.001 2.17 (2.10–2.23) ,0.001
Male 0.80 (0.78–0.82) ,0.001 0.75 (0.73–0.77) ,0.001
Myocardial infarction 1.09 (1.05–1.13) ,0.001 1.12 (1.08–1.17) ,0.001
Peripheral vascular disease 1.10 (1.06–1.14) ,0.001 0.98 (0.95–1.02) NS
Parentheses indicate 95% confidence intervals.
The rate ratio is a multiplicative factor indicating the relative time hospitalized compared with the alternative for that variable, with ratio .1 indicating a higher
rate of hospitalization. The comparators are hemodialysis, age , median, chronic onset of renal failure, no cardiac failure, no diabetes, female, no myocardial
infarction, and no peripheral vascular disease. NS is not statistically significant.
Table 4. Hospitalization rates (hospital days/1000 patient-days) for specific diagnoses according to mode of dialysis used
at baseline and three months
Baseline Month 3
HD PD HD PD
(N 5 540) (N 5 279) P value (N 5 340) (N 5 349) P value
Cardiovasculara 9.92 9.55 NS 6.53 13.73 ,0.001
Cardiac failure 2.11 1.93 NS 1.62 2.02 0.001
Gastro-intestinal disease 2.57 1.95 ,0.001 2.50 2.32 NS
Malignancy 0.93 0.48 ,0.001 0.68 0.78 NS
Infection (not dialysis related) 6.51 1.67 ,0.001 4.89 2.42 ,0.001
Surgery (not dialysis related) 0.99 1.11 NS 1.21 1.07 NS
Dialysis access creation 1.80 1.39 ,0.001 0.78 1.28 ,0.001
Peritonitis 2.19 4.99 ,0.001 0.77 6.30 ,0.001
Line infection 1.00 0.14 ,0.001 1.00 0.16 ,0.001
Other dialysis 2.71 4.46 ,0.001 1.85 2.03 NS
All dialysisb 10.03 12.00 ,0.001 7.37 12.78 ,0.001
All diagnoses 43.68 33.23 ,0.001 32.99 42.79 ,0.001
Abbreviations are: HD, hemodialysis; PD, peritoneal dialysis; NS, not statistically significant.
aIncludes days hospitalized for angina, myocardial infarction, peripheral vascular disease, stroke and TA
bIncludes days hospitalized for access creation, access infection, peritonitis, graft/fistula thrombosis, dialysis inadequacy, and other dialysis-related reasons
DISCUSSION therapy, however, or when the treatment actually re-
ceived was the basis for analysis, PD patients spent moreIn this inception cohort of Canadian dialysis patients,
time in the hospital than their HD counterparts.there were substantial differences in comorbidity-adjusted
The initially higher hospitalization rate seen in HDhospitalization rates between patients treated with HD
patients was despite the fact that hospital admissionsand PD. Patients initially treated with HD had a higher
that started before or coincided with the first dialysisburden of comorbid illness and a higher incidence of
treatment were not included in the analysis. This wasacute onset of renal failure compared with those on PD.
done because patients who develop renal failure whileWhen analyzed in a strict intention-to-treat manner, pa-
in the hospital or, alternatively, who have symptoms oftients treated with PD as their first therapy had a signifi-
renal failure severe enough to require hospital admissioncantly lower hospitalization rate compared with patients
will be preferentially treated with HD as their first dial-treated with HD. When the starting point for analysis
was considered to be three months after initiating dialysis ysis modality. Nonetheless, it is possible that unmeasured
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comorbidity over and above that which was adjusted for reasons, which consisted of such events as dialysis train-
ing and hernia repairs in preparation for PD.is responsible for the observed difference. In intention-
to-treat studies of patient outcome related to mode of When the groups were defined by the treatment in
use at three months and only hospitalizations after thisdialysis, it has been become common to assign treatment
groups according to the prevalent mode of dialysis at 90 point were considered, however, several differences were
seen. First, the hospitalization rate for cardiovasculardays, as a substantial proportion of patients switch dial-
ysis modality in this initial period of time. disease and cardiac failure were higher in PD patients
relative to HD patients. Second, hospitalized days forA major problem in observational studies of dialysis
modality is treatment crossover. In this cohort, approxi- infectious illness not related to dialysis in HD patients
continued to be higher than that in PD patients. Finally,mately 10% of HD patients and 30% of PD patients had
at least one switch of therapy even after the first three- hospitalizations directly related to dialysis remained ap-
proximately the same in PD patients, but declined some-month period. Poisson regression is well suited to this
type of analysis in that the unit of analysis is the person what in HD patients. The reasons for the first two obser-
vations are not clear, but may be related to case-mixtime spent on each treatment rather than individual sub-
jects, and thus, a single patient may contribute time to differences. Studies directly comparing hospitalization
resulting from cardiovascular disease in these two modesone or both treatment groups. The assignment of out-
come events to treatment groups is more arbitrary but, of dialysis are lacking. Prevalence rates have generally
appeared to be higher in the HD population, but therein this case, was based on the mode of dialysis in use
the day a hospital admission began. This is entirely ap- is a clear imbalance in the presence of established disease
at the inception of treatment [20, 21]. Similarly, therepropriate for admissions that are precipitated by rela-
tively acute events, such as dialysis-related technical are few studies directly comparing morbidity from infec-
tions, other than those directly related to dialysis tech-problems, infection, and fluid overload, but less so for
admissions related to chronic illnesses. Despite this limi- nique. Maiorca et al, however, found no difference in
hospitalized days for infection at their center for patientstation, however, treatment-received analyses offer useful
insight into the “real world” effect of dialysis modality on on PD versus those on HD [12]. There is some indirect
evidence that PD may be more effective in improvingpatient outcome that is complimentary to that obtained
from intention-to-treat models. In our study, the treat- uremic immunity than HD [22–24].
The difference in the hospitalization rate for dialysis-ment-received analyses clearly indicate a higher rate of
hospitalization associated with PD. related reasons is also difficult to interpret. Potential
explanations include the possibility that some of the pa-Our results correspond with those described in a num-
ber of previous studies [9–15]. In their analysis of 1988– tients classified as HD in the first three months are hospi-
talized during the initial period for reasons related to1990 U.S. Renal Data System prevalent cohort data,
Habach et al found an admission rate of 14% higher and PD, to which they later switch, or that patients on PD
are more commonly not residents of major centers anda total hospitalization rate of 26% higher in PD patients
after adjustment for race, age, gender, diabetes, and are therefore admitted to the hospital rather than offered
outpatient treatment.cause of end-stage renal disease [9]. Burton and Walls
used linear modeling to identify and adjust for several The current study has several attractive features for an
observational design. It is based on an inception cohort ofcofactors in a retrospective study of 227 dialysis patients.
While the magnitude of the risk varied greatly with time, patients, with patients enrolled immediately prior to
their first dialysis treatment. In any nonrandomized ob-the estimated PD:HD risk ratio for hospitalization was
1.33 (95% CI, 0.85 to 2.09) for that portion of the cohort servational study, selection bias is a major concern. Nu-
merous previous studies have shown an imbalance inbeginning treatment in 1985, the latter end of the study
period [9]. comorbidity in patients treated with PD versus HD, with
the majority of them indicating more comorbid illnessThe reasons for hospitalization of the two groups of
patients were substantially different. When all hospital- in the former group [6, 10, 25]. In the cohort used in
this study, detailed data on the presence and severity ofizations were analyzed according to the initial mode of
dialysis used, there were more hospitalized days for most illness were rigorously collected in a prospective manner,
allowing for adjustment for these factors. In addition tocategories of admission diagnoses in the HD group. This
is not surprising given the higher baseline comorbidity comorbid illness, we also considered the effect of acuity
of onset of renal failure on subsequent hospitalization.and the higher incidence of acute or acute-on-chronic
onset of renal failure in this group. The hospitalization Other advantages of the current study lie in the fact that
the 11 centers represent a broad national sample andrate for the aggregate group consisting of all dialysis-
related causes, however, was higher in the PD group. the cohort assembly period was relatively brief, minimiz-
ing the potential effects of changing dialysis technologyThis is partly explained by an excess of admissions for
peritonitis and also by the admissions for “other dialysis” and techniques over time.
Murphy et al: Hospitalization in HD versus PD in Canada 2563
continuous ambulatory peritoneal dialysis and center hemodialysis.Because this study is not a randomized trial, there are
Arch Int Med 146:1138–1143, 1986
many factors contributing to selection bias in dialysis 6. Gokal R, Jakubowski C, King J, Hunt L, Bogle S, Baillod R,
Marsh F, Ogg C, Oliver D, Ward M, Wilkinson R: Outcomemodality choice that cannot be adjusted for. Differences
in patients on continuous ambulatory peritoneal dialysis and hemo-in education, socioeconomic status, family supports, and
dialysis: A 4-years analysis of a prospective multicenter study.
patient attitudes are examples of variables that are likely Lancet 2:1105–1108, 1987
7. Singh S, Yium J, Macon E, Clark E, Schaffer D, Teschan P:to influence patient outcome, including hospitalization,
Multicenter study of change in dialysis therapy: Maintenance he-but are not accounted for in our study. The current study
modialysis to continuous ambulatory peritoneal dialysis. Am J
was not designed to investigate the influence of dialysis Kidney Dis 3:246–251, 1992
8. Serkes K, Blagg CR, Nolph KD, Vonesh EF, Shapiro F: Compar-adequacy or compliance on patient outcome. Data per-
ison of patient and technique survival in continuous ambulatorytaining to this were not systematically collected as part
peritoneal dialysis (CAPD) and hemodialysis: A multicenter study.
of the study protocol. Those data that were available, Perit Dial Int 10:15–19, 1990
9. Habach G, Bloembergen WE, Mauger EA, Wolfe RA, Fried-although incomplete, suggest that neither group was
rich K: Hospitalization among United States dialysis patients: He-grossly underdialyzed and that these patients are repre- modialysis versus peritoneal dialysis. J Am Soc Nephrol 5:1940–
sentative of the standard dialysis practice in Canada dur- 1948, 1995
10. Burton PR, Walls J: A selection adjusted comparison of hospital-ing the study period. Finally, it is possible that not all
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